Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models

BACKGROUND: Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal adenocarcinoma progression by inhibition of Txnrd1 and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Surg Open Sci
Main Authors: Rios Perez, Mayrim V., Roife, David, Dai, Bingbing, Pratt, Michael, Dobrowolski, Ryszard, Kang, Ya'an, Li, Xinqun, Augustine, Jithesh J., Zielinski, Rafal, Priebe, Waldemar, Fleming, Jason B.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8083010/
https://ncbi.nlm.nih.gov/pubmed/33981979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.sopen.2019.05.004
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki